Free tool
FAERS Monitor: Edarbyclor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202331 or its brand name (Edarbyclor, Azilsartan Kamedoxomil, Chlorthalidone). Reports on generic versions are filed under their own applications.
Reports
1,259
Serious
648
51% of reports
Hospitalization
222
Death reported
39
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness108
- fatigue78
- blood pressure increased72
- drug ineffective67
- diarrhoea62
- nausea62
- hypotension58
- hypertension56
- headache55
- asthenia49
- hyponatraemia47
- dyspnoea44
- muscle spasms44
- pain39
- pneumonia38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 33 |
| 2013 | 31 |
| 2014 | 46 |
| 2015 | 68 |
| 2016 | 189 |
| 2017 | 144 |
| 2018 | 131 |
| 2019 | 133 |
| 2020 | 119 |
| 2021 | 76 |
| 2022 | 53 |
| 2023 | 80 |
| 2024 | 62 |
| 2025 | 60 |
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,900 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyponatraemiaSignal | 47 | 14.0 | 10.5 | 553 |
| blood pressure increasedSignal | 72 | 7.9 | 6.3 | 428 |
| hypotensionSignal | 58 | 4.8 | 3.8 | 174 |
| hypertensionSignal | 56 | 4.4 | 3.4 | 146 |
| muscle spasmsSignal | 44 | 4.0 | 3.0 | 97 |
| dizzinessSignal | 108 | 3.6 | 3.0 | 207 |
| astheniaSignal | 49 | 2.2 | 1.7 | 31 |
| pneumonia | 38 | 2.0 | 1.4 | 17 |
| fatigue | 78 | 1.7 | 1.4 | 21 |
| diarrhoea | 62 | 1.6 | 1.3 | 14 |
| headache | 55 | 1.5 | 1.1 | 8 |
| nausea | 62 | 1.3 | 1.0 | 4 |
| dyspnoea | 44 | 1.3 | 1.0 | 3 |
| pain | 39 | 1.1 | 0.8 | 0 |
| drug ineffective | 67 | 0.8 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.